Body surface mapping of P-waves in sinus rhythm to predict recurrence following cardioversion for atrial fibrillation.
atrial fibrillation
body surface mapping
cardioversion
electrical cardioversion
p-waves
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2024
2024
Historique:
received:
13
04
2024
accepted:
15
07
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
9
8
2024
Statut:
epublish
Résumé
Direct current cardioversion (DCCV) is used as elective and emergency rhythm control for atrial fibrillation (AF). We aimed to explore the role of P-wave parameters measured during sinus rhythm using body surface mapping (BSM) in predicting successful DCCV for persistent atrial fibrillation (persAF) at 12 months. This case-control study included 56 males >18 years old who underwent DCCV for persAF. P-wave parameter collection after DCCV for AF was done using 128 unipolar leads. A band-pass filter of 1-50 Hz was utilised. Corrected P-wave duration (PWDc), P-wave amplitude, and P-wave dispersion were measured to predict 12-month outcomes and time of recurrence. The mean age was 64 ± 4 years, and 23 patients (44%) were on amiodarone. The 12-month success rate was 44% ( In patients on amiodarone, increased PWDc measured using BSM was associated with higher AF recurrence at 12 months following DCCV for persAF.
Sections du résumé
Background
UNASSIGNED
Direct current cardioversion (DCCV) is used as elective and emergency rhythm control for atrial fibrillation (AF). We aimed to explore the role of P-wave parameters measured during sinus rhythm using body surface mapping (BSM) in predicting successful DCCV for persistent atrial fibrillation (persAF) at 12 months.
Methods
UNASSIGNED
This case-control study included 56 males >18 years old who underwent DCCV for persAF. P-wave parameter collection after DCCV for AF was done using 128 unipolar leads. A band-pass filter of 1-50 Hz was utilised. Corrected P-wave duration (PWDc), P-wave amplitude, and P-wave dispersion were measured to predict 12-month outcomes and time of recurrence.
Results
UNASSIGNED
The mean age was 64 ± 4 years, and 23 patients (44%) were on amiodarone. The 12-month success rate was 44% (
Conclusion
UNASSIGNED
In patients on amiodarone, increased PWDc measured using BSM was associated with higher AF recurrence at 12 months following DCCV for persAF.
Identifiants
pubmed: 39119182
doi: 10.3389/fcvm.2024.1417029
pmc: PMC11306046
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1417029Informations de copyright
© 2024 Antoun, Li, Kotb, Barker, Mavilakandy, Koev, Vali, Somani and Ng.
Déclaration de conflit d'intérêts
AK is supported with a clinical research fellowship from Abbott. GAN is supported by a British Heart Foundation Programme Grant (RG/17/3/32,774) and the Medical Research Council Biomedical Catalyst Developmental Pathway Funding Scheme (MR/S037306/1). GAN also discloses consultancy fees, speaker honorarium fellow support from Biosense Webster, research fellow funding from Abbott, and consultancy fees from Catheter Precision. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.